Evotec AG reports results of first quarter 2015

– VERY STRONG START TO 2015: 22% GROWTH OF GROUP REVENUES, MAINLY DRIVEN BY EVT EXECUTE – MAJOR MULTI-COMPONENT STRATEGIC ALLIANCE WITH SANOFI CLOSED- FULL-YEAR REVENUE GUIDANCE RAISED   Hamburg, Germany – 12 May 2015: … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-reports-results-of-first-quarter-2015-5285

Weiterlesen

Facio partners with Evotec and initiates FSHD drug discovery programme

Evotec AG and Facio Therapies announced today that they have entered into an agreement aimed at the identification of compounds showing activity as a potential treatment to stop the progression of FSHD, a muscle wasting disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/facio-partners-with-evotec-and-initiates-fshd-drug-discovery-programme-5281

Weiterlesen

Asahi Kasei Pharma selects Evotec as its partner for ion channel drug discovery

Evotec AG today announced it has entered into a multi-target screening collaboration on several ion channel targets, with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/asahi-kasei-pharma-selects-evotec-as-its-partner-for-ion-channel-drug-discovery-5279

Weiterlesen

Evotec and Sanofi sign definitive agreement for major multi-component strategic alliance

Evotec AG today announced that a definitive agreement for a major multi-component strategic alliance over the next five years has been signed with Sanofi. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-sanofi-sign-definitive-agreement-for-major-multi-component-strategic-alliance-5273

Weiterlesen

Second Genome and Evotec to collaborate in microbiome discovery and development

Evotec AG and Second Genome, Inc. today announced a collaboration in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/second-genome-and-evotec-to-collaborate-in-microbiome-discovery-and-development-5269

Weiterlesen

Evotec achieves further milestones in TargetAD collaboration with Janssen

Evotec AG today announced the achievement of several small, but very important milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the identification and selection of novel targets from Evotec’s TargetAD database and for the transition of targets into the drug discovery process. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-further-milestones-in-targetad-collaboration-with-janssen-5263

Weiterlesen

Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration

Evotec AG and Padlock Therapeutics, Inc. announced today that they have successfully completed an initial goal in a programme focused on developing inhibitors of protein-arginine deiminases and have further extended the collaboration that was first signed in January 2014. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-padlock-therapeutics-announce-initial-success-and-extension-of-long-term-collaboration-5261

Weiterlesen

Evotec and Ohio State to collaborate on novel cancer therapy

Evotec AG today announced a research collaboration with the laboratories of Prof. Roger Briesewitz at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-ohio-state-to-collaborate-on-novel-cancer-therapy-5259

Weiterlesen